KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Ratio: 2020-2025

Historic Equity Ratio for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to 0.75.

  • Recursion Pharmaceuticals' Equity Ratio rose 3.61% to 0.75 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75, marking a year-over-year increase of 3.61%. This contributed to the annual value of 0.71 for FY2024, which is 0.76% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Equity Ratio stood at 0.75, which was up 6.00% from 0.71 recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Equity Ratio ranged from a high of 0.92 in Q2 2021 and a low of -0.86 during Q1 2021.
  • Moreover, its 3-year median value for Equity Ratio was 0.71 (2024), whereas its average is 0.72.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Equity Ratio surged by 228.76% in 2021, and later slumped by 30.24% in 2022.
  • Recursion Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.89 in 2021, then dropped by 22.13% to 0.69 in 2022, then rose by 2.34% to 0.71 in 2023, then increased by 0.76% to 0.71 in 2024, then grew by 3.61% to 0.75 in 2025.
  • Its Equity Ratio stands at 0.75 for Q3 2025, versus 0.71 for Q2 2025 and 0.72 for Q1 2025.